Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 165-172 , February 2006

In vitro metabolism studies of 18F-labeled 1-phenylpiperazine using mouse liver S9 fraction

Received 18 May 2005 ,Revised 26 November 2005 ,Accepted 4 December 2005.

References 

  1. Delaforge M. Importance of metabolism in pharmacological studies: possible in vitro predictability. Nucl Med Biol. 1998;25:705–709
  2. Mazel P. General principles and procedures for drug metabolism in vitro. In:  La Du BN,  Mandel HG,  Way EL editor. Fundamentals of drug metabolism and drug deposition. Baltimore: The Williams & Wilkins Company; 1971;p. 527–545
  3. Mazière B, Cantineau R, Coenen HH, Guillaume M, Halldin C, Luxen A, et al. PET radiopharmaceutical metabolism — plasma metabolite analysis. In:  Stöcklin G,  Pike VW editor. Radiopharmaceuticals for positron emission tomography. Methodological aspects. Dordrecht: Kluwer Academic Publishers; 1993;p. 151–178
  4. Mach RH, Nowak PA, Moroney DA, Morton TE, Jackson JR, Ehrenkaufer RLE. Synthesis and in vivo evaluation of [18F]-N-(p-nitrobenzyl)spiperone ([18F]PNBS) in rats. Nucl Med Biol. 1993;20:269–278
  5. Welch MJ, Katzenellenbogen JA, Mathias CJ, Brodack JW, Carlson KE, Chi DY, et al. N-(3-[18F]Fluoropropyl)-spiperone: the preferred 18F labeled spiperone analog for positron emission tomographic studies of the dopamine receptor. Nucl Med Biol. 1988;15:83–97
  6. Tan P-Z, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, et al. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol. 1999;26:601–608
  7. Lee S-Y, Choe YS, Kim DH, Park B-N, Kim SE, Choi Y, et al. A simple and efficient in vitro method for metabolism studies of radiotracers. Nucl Med Biol. 2001;28:391–395
  8. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975;31:347–364
  9. Liu K, Guengerich P, Yang SK. Enantioselective hydrolysis of lorazepam 3-acetate by esterases in human and rat liver microsome and rat brain S9 fraction. Drug Metab Dispos. 1991;19:609–613
  10. Li AP, Hartman NR, Lu C, Collins JM, Strong JM. Effects of cytochrome P450 inducers on 17α-ethynyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol. 1999;48:733–742
  11. Yoshihara S, Makishima M, Suzuki N, Ohta S. Metabolic activation of bisphenol A by rat liver S9 fraction. Toxicol Sci. 2001;62:221–227
  12. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986;261:5051–5060
  13. Haka MS, Kilbourn MR, Watkins GL, Toorongian SA. Aryltrimethylammonium trifluoromethanesulfonates as precursors to aryl [18F]fluoride: improved synthesis of [18F]GBR-13119. J Labelled Compd Radiopharm. 1989;27:823–833
  14. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal Biochem. 1976;72:248–254
  15. Choe YS, Oh SJ, Shim I, Naruto S, Chi DY, Kim SE, et al. Syntheses and biological evaluation of 18F-labeled 3-(1-benzyl-piperidin-4-yl)-1-(1-methyl-1H-indol-3-yl)propan-1-ones for in vivo mapping of acetylcholinesterase. Nucl Med Biol. 2000;27:263–267
  16. Ma Y, Lang L, Kiesewetter DO, Jagoda E, Sassaman MB, Der M, et al. Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-{2-[4-(2-methoxyphenyl)piperazino]ethyl}-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. J Chromatogr B. 2001;755:47–56
  17. Lee KC, Lee S-Y, Choe YS, Chi DY. Metabolic stability of [18F]fluoroalkylbiphenyls. Bull Korean Chem Soc. 2004;25:1225–1230
  18. Magata Y, Lang L, Kiesewetter DO, Jagoda EM, Channing MA, Eckelman WC. Biologically stable [18F]-labeled benzylfluoride derivatives. Nucl Med Biol. 2000;27:163–168

PII: S0969-8051(05)00297-0

doi: 10.1016/j.nucmedbio.2005.12.002

Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 165-172 , February 2006

Article Tools

* Image Usage & Resolution